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(14≤ age≤ 75 years) with class I, IIa, or IIb MG according to Osserman’s classifica-
tion are enrolled, and are blindly separated into Chinese herb group and control 
group. The Chinese herb group is treated with Huangqi formula and control group 
with placebo, treatment duration is four weeks. Muscle weakness is assessed by 
Chinese Score for MG (CSMG; rang 12-60; higher scores worse weakness), and QoL 
is assessed by the SF-36 (rang: 0-100; higher scores better QoL); Both CSMG and 
SF-36 are evaluated at the enrollment and after four-week treatment. Results: 
Analysis is based on 248 patients (male 110, 44%; age:46±18 year), of whom 125 
patients randomized into the Chinese herb group and 121 finish the treatment; 
123 in the control group and 120 finish the study. There is no significant differ-
ence in demographic and clinical characteristics between two groups (P> 0.05), and 
no difference in CSMG (Chinese herb vs control groups: 24.1±5.9 vs 23.3±6.6) and 
SF-36 (55.7±16.6 vs 57.7±16.5) at the baseline either. After four-week treatment, 
muscle weakness declined 6.4±5.0 in Chinese herb group and 1.0±3.8 in control 
group (P= 0.000). However, no significant changes are found in SF-36 scores between 
the two groups (56.7±16.1 and 57.1±15.9). ConClusions: This study proves that 
Chinese herb can relieve MG patients’ muscle weakness, but it is not enough to 
improve patients’ QoL in four weeks.
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objeCtives: To examine if: (1) time to initiation (TTI) of biologic DMARD therapy 
(B-DMARD) differs by non-biologic DMARD (NB-DMARD) type and therapy; and 
(2) likelihood of initiation of B-DMARD differs by NB-DMARD type and therapy 
while controlling for covariates. Methods: Texas Medicaid medical and pre-
scription claims from 7/1/03-12/31/10 were extracted for adults (18-63 years) 
who were diagnosed with rheumatoid arthritis (ICD-9 CM 714.0x) with no use of 
DMARDs in the preindex period. The index date was the first date of NB-DMARD 
use. The likelihood of initiating B-DMARDs was compared among on NB-DMARD 
type [methotrexate(MTX), sulfasalazine(SSZ), hydroxychloroquine(HCQ), 
leflunomide(LEF)] and NB-DMARD therapy (mono vs. dual), while controlling for 
demographic factors (age, gender, race), NB-DMARD adherence [proportion of days 
covered (PDC)≥ 70% vs. < 70%], persistence, pain medication, glucocorticoid use, and 
Charlson Comorbidity Index score (CCI). Descriptive statistics, Kaplan-Meier, Log-
rank test, and logistic regression were utilized. Results: The subjects (n= 2,714) 
were 48.1±10.4 years old, primarily female (89.1%), and Hispanic (55.3%). The major-
ity were on pain medications (92.4%), glucocorticoid users (64.9%), and NB-DMARD 
monotherapy users (86.4%); while, 24.3% initiated on B-DMARDs and 46.7% had a 
CCI score= 1. Compared to TTI (days) of B-DMARDs for MTX (208.3±190.1) users, TTI of 
B-DMARDs was longer for SSZ (284.5±186.4) and HCQ (256±184.4) users and shorter 
for LEF users (188.0±205.1);p< 0.0001). There were no differences between mono 
and dual therapy users. After controlling for covariates, regression results showed 
that compared to MTX, SSZ users were 66.8% less likely (OR= 0.322;95%CI= 0.237-
0.464;p< 0.0001) and HCQ users were 79.0% less likely (OR= 0.210;95%CI= 0.160-
0.278;p< 0.0001) to initiate B-DMARD therapy. NB-DMARD monotherapy users were 
47.5% more likely (OR= 1.475;95%CI= 1.121-1.940;p< 0.0001) to initiate B-DMARD 
therapy compared to dual therapy users. ConClusions: Time to B-DMARD ini-
tiation ranged from 6.3 (LEF) to 9.5 months (SSZ). Patients who used NB-DMARD 
MTX and those on monotherapy may be more likely to initiate on B-DMARD therapy.
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In April 2013, percutaneous vertebroplasty (PVP) and balloon kyphoplasty (BKP) 
without stenting—two vertebral augmentation procedures—were recommended 
by NICE to treat vertebral compression fractures (VCFs) due to osteoporosis (TA279). 
Although all-cause mortality was assessed as a secondary outcome, evidence from 
included RCTs did not achieve statistical significance, even when pooled, comparing 
operated patients (PVP or BKP) to patients receiving only optimal pain management 
(OPM). The Evidence Review Group stated that the effect of vertebral augmentation 
on mortality was an important, yet inadequately understood issue, despite evi-
dence of improved survival from recently published large-scale registry studies from 
Germany and the United States. objeCtives: To estimate the mortality differences 
between treatments for osteoporotic VCFs by pooling randomised and observa-
tional data using Cox regression, propensity score matching, as well as, Thompson 
et al.’s (2010) and Welton et al.’s (2009) bias adjustment methods. Methods: We 
extended the random effects meta-analysis from NICE’s TA279 to include observa-
tional data extracted from German and US (Medicare) insurance claims databases 
to estimate the mortality effect of PVP versus OPM and BKP versus OPM. All adjust-
ment methods were compared and evaluated using a simple cost-effectiveness 
model. PReliMinARy Results: Survival hazard ratios were statistically significant, 
using all methods, in favour of either vertebral augmentation procedures versus 
OPM. The uncertainty in resulting estimates was artificially inflated to assess the 
level of uncertainty required to reach < 50% probability of cost-effectiveness at 
common threshold values. Mortality benefit was shown to be a key driver of cost-
effectiveness, particularly for BKP. ConClusions: Cox regression and propensity 
scoring adjustments are reliant on covariate information and thus may not capture 
all sources of bias; other proposed adjustment methods may play a pivotal role in 
assessing real-word evidence. An application of these methods to network meta-
analysis is currently being undertaken to simultaneously compare operated patients 
with patients receiving OPM.
Among biologic monotherapies, greater ACR20/50/70 responses were observed with 
TCZ IV than with aTNFs and tofacitinib. When comparing biologics + MTX with 
biologic monotherapies, ACR20, ACR50, and ACR70 responses with TCZ + MTX were 
similar to TCZ as monotherapy (OR= 1.04, 95% CI, 0.39-2.80; OR= 1.28, 95% CI, 0.46-
3.51; OR= 0.97, 95% CI, 0.38-2.49, respectively). Greater ACR20/50/70 responses were 
observed with aTNF + MTX than with aTNF monotherapy (OR= 2.22; 95% CI, 0.46-
10.83, probability better= 84%; OR= 3.12, 95% CI, 0.60-16.32, probability better= 92%; 
OR= 1.39, 95% CI, 0.26-6.78, probability better= 68%, respectively). Sensitivity analyses 
showed conflicting results for the indirect comparison of tofacitinib + MTX versus 
tofacitinib. ConClusions: Results suggest that most of the novel DMARDs, in 
combination with MTX, have similar levels of efficacy in DMARD-IR patients. As 
monotherapy, TCZ is likely to have a greater response than aTNFs and tofacitinib. 
TCZ monotherapy also shows comparable efficacy compared to TCZ + MTX, whereas 
aTNFs in combination with MTX showed greater ACR responses compared with 
aTNF monotherapy at 24 weeks.
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Meta-analySiS oF eFFicacy oF etanercePt For PSoriatic arthritiS
Aggarwal S., Topaloglu H., Segal J.
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objeCtives: Psoriatic arthritis (PA) is an inflammatory disease affecting joints and 
connective tissues. The anti-tumor necrosis factor (TNF) biologics are increasingly 
being used in patients who have failed traditional disease-modifying antirheumatic 
drugs. Etanercept has shown efficacy in treatment of PA. The objective of this study 
was to conduct meta-analysis and present total evidence for etanercept in treatment 
of PA. Methods: For this meta-analysis we included randomized controlled trials 
(RCTs)evaluating etanercept for the treatment of PS. RCTs studying adult popu-
lations with active and progressive PA with an inadequate response to previous 
DMARD therapy were eligible. Trials conducted among PA populations with prior 
experience with anti-TNF agents, including an inadequate response, were excluded. 
A systematic literature search for Etanercept trials was undertaken for the databases 
Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was collected for the 
study size, interventions, year, and the three outcomes HAQ, PASI and PsARC. For 
meta-analysis, random effects and fixed effects models were used to obtain cumula-
tive statistics. Results: Two RCTs with a total of 131 patients were identified. The 
pooled response rates for Etanercept for PsARC were 75% (95% CI 60%-90%), for HAQ 
were 59% (95% CI 46%-72%), and for PASI were 24% (95% CI 13%-34%). The pooled 
response rates for placebo for PsARC were 30% (95% CI 26%-35%), for HAQ were 5% 
(95% CI 1%-9%), and for PASI were 3% (95% CI 0%-7%). For PsARC the cumulative 
relative risk with Etanercept versus placebo was 0.40 (95% CI 33%-48%). For HAQ, the 
cumulative relative risk with placebo versus Etanercept was 0.08 (95% CI 5%-12%). 
For PASI, the cumulative relative risk with placebo versus Etanercept was 0.14 (95% 
CI 8%-20%). ConClusions: Meta-analysis shows Etanercept offers patients with 
psoriatic arthritis an effective therapeutic option for control of their disease.
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objeCtives: Certolizumab pegol (CZP) is an anti-TNF approved for rheumatoid 
arthritis (RA) in the UK. Based on 12 week clinical data, NICE guidance recommends 
CZP as first-line biologic therapy for RA treatment, in conjunction with a Patient 
Access Scheme (PAS) providing the initial 12 weeks of CZP free of charge to UK NHS. 
The objective was to assess real-world CZP utilization. Methods: A retrospec-
tive, observational cohort analysis was conducted in four UK Rheumatology clinics. 
Chart data was collected for biologic-naïve RA patients initiating CZP, followed up 
to 52 weeks. Reported data included: baseline characteristics, persistence at Weeks 
12/24/52, concomitant medication and PAS cost impact. Results: 110 CZP patients 
were analysed. Baseline characteristics: mean age 57.4 years, 65.5% female, mean 
DAS 6.1. Data was collected for 110, 108 and 82 patients over 12, 24 and 52 weeks, 
respectively (a certain number of patients’ data was only available for portions 
of the 52-week retrospective follow-up). At baseline, 68.2% patients received con-
comitant methotrexate, 28.2% oral corticosteroids, and 14.5% CZP monotherapy. 
Kaplan-Meier persistency estimates were: 95.5%, 82.6% and 71.8% at 12, 24, 52 weeks, 
respectively. Assuming full compliance with labeled dosing, CZP cost for 52 weeks 
therapy was £10,368 per patient in England/Wales and £6,793 with the 12 weeks for 
free PAS applied. This is £2,502 and £2,363 less than comparable annual per-patient 
costs for etanercept and adalimumab, respectively. ConClusions: CZP persistency 
appeared consistent with data observed in other observational studies of subcu-
taneous anti-TNFs. Application of the PAS resulted in a substantial reduction in 
1-year costs for CZP therapy in comparison to alternatives. PAS-related savings, 
adjusted for real-world persistency, will also help provide Payers with data to make 
informed decisions for options to treat RA. Interpretation of data is limited due to 
retrospective analysis caveats.
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iS chineSe herB eFFective on treating MyaSthenia graviS PatientS?
Zhang H.Y., Xie W.F., Zhang J.S., Yang G.L.
Liaoning University of Traditional Chinese Medicine, Shenyang, China
objeCtives: Myasthenia Gravis (MG) is an auto immune disease of neuromuscular 
junction, which leads to muscle weakness and influences patients’ quality of life 
(QoL). Treatments for MG patients include thymectomy, acetylcholinesterase inhibi-
tors and immunosuppressant drugs. But in China, Chinese herb is widely used. This 
study is to prove Chinese herb’s efficacy on treating MG patients. Methods: The 
data is performed on a random double blind clinical trial. Consecutive MG patients 
are enrolled in three hospitals in China, from July, 2008 to June, 2010. Patients 
